PolyPhotonix, a bio-photonic research and development company in the North East, has secured a six-figure investment from NPIF-FW Capital Debt Finance. The investment will assist in promoting their innovative product, the Noctura 400 Mask, which helps to prevent blindness caused by diabetic retinopathy. The Noctura 400 Mask is a non-invasive, home-based monitored treatment that delivers low levels of light through closed eyelids during sleep. This prevents retinal hypoxia and manages the nocturnal oxygen demand of the retina during the night. Clinical trials have proven that it improves or stabilizes sight loss in patients with diabetes.
Traditionally, patients with early signs of retinopathy are simply monitored until they qualify for treatment, which is currently invasive and expensive. However, by offering the Noctura 400 Mask at this early stage, patients’ vision can be preserved and referrals into clinics are reduced, saving approximately £3K per patient per year. With this investment from NPIF-FW Capital Debt Finance, PolyPhotonix aims to promote the product in the UK following its partnership agreement with Embecta, one of the largest diabetic treatment companies in the world. The Noctura 400 received UK NHS approval in November 2022, and other countries have also granted regulatory approvals.
Richard Kirk, CEO of PolyPhotonix, praised the Noctura 400 Mask for its accessibility, ease of use, and effective results. He also emphasized the importance of the partnership with Embecta in bringing the product to more patients globally. Keith Charlton, Fund Manager at FW Capital, expressed his delight in helping PolyPhotonix achieve its goals and praised the business for its transformational impact on diabetic eye care. Additionally, Keira Shepperson, Director of British Business Bank, highlighted the innovation of Northern businesses and their contribution to a thriving economy.
In conclusion, the Noctura 400 Mask is a game-changer in the field of diabetic treatment, and PolyPhotonix is committed to promoting its accessibility and affordability to patients worldwide. With the support of NPIF-FW Capital Debt Finance and its partnership with Embecta, the company is poised to transform the way diabetic retinopathy is treated.
